MINX · Precision Dutasteride · Diazoxide

Every Hair Loss Treatment, Ranked (2026): Our Tier List

Our hair loss treatment tier list ranks 56 treatments, from the best-studied drugs (finasteride, dutasteride and minoxidil) to PRP and rosemary oil, with the human evidence behind each placement and its limits.

56
treatments ranked
six tiers, S to F
+138
hairs vs placebo, finasteride 1 mg
two years, 5.1 cm² crown patch
0
S tier treatments with a hair-count trial

Key takeaways

  • Finasteride, dutasteride and minoxidil have the most placebo-controlled hair count data on this list, from trials of hundreds to thousands of people.
  • Our S tier is a judgement on mechanism alone. It holds two Anagen products, MINX (minoxidil) and Precision Dutasteride 1%, plus two lab-stage mechanisms, and none of the four has a hair-count trial of its own.
  • PRP, laser helmets, Nutrafol, saw palmetto, pumpkin seed oil and caffeine all have human trials. They rank in F because the trials we found are small, short, uncontrolled, maker-funded or rated low quality.
  • Several of the newest results, including pyrilutamide, clascoterone, PP405 and ET-02, are company announcements with no peer-reviewed paper.
Contents8 sections

On 15 November 2026 we posted our hair loss treatment tier list on X: 56 treatments in six tiers, S to F. The card reads "Our read of mechanism plus human evidence. Not a trial ranking." Below is the strongest evidence we found for each placement, and where that evidence is thin.

The short answer: Finasteride, dutasteride and minoxidil have the most placebo-controlled hair count data, and they sit in our A tier. S tier holds two Anagen products that contain those drugs, MINX and Precision Dutasteride 1%, plus two lab-stage mechanisms, TWIST1 inhibition and R-spondin. None of the four has a hair-count trial of its own. Twenty-two treatments sit in F, including PRP, laser helmets, rosemary oil and Nutrafol.

TierTreatments
STWIST1 inhibitor, R-spondin, MINX, Precision Dutasteride 1%
ADutasteride, finasteride, minoxidil, diazoxide, 17β-estradiol
BMicroneedling, RU58841, bicalutamide, darolutamide, dimethylcurcumin
CWAY-316606, ABS-201, KY19382, fluridil, T3, ketoconazole, latanoprost, bimatoprost, clascoterone, ET-02
DGHK-Cu, levocetirizine, melatonin, progesterone, pyrilutamide, adenosine, NAC ethyl ester, PP405, HMI-115, hyaluronic acid
FPumpkin seed oil, rosemary oil, vitamins, mineral oils, alfatradiol, BPC-157, methyl vanillate, caffeine, methyl nicotinate, arginine, pentoxifylline, CosmeRNA, Stemoxydine, minoxidil sulfate, saw palmetto, carpronium chloride, scalp massage, laser helmets, PRP, Nutrafol, deoxyribose gel, SCUBE3

How did we rank hair loss treatments?

We ranked each treatment on two things together. Does its mechanism act on what drives pattern hair loss? And how strong is the human evidence?

Pattern hair loss is caused by androgen-dependent shrinking of scalp follicles, with DHT a contributing cause (Kaufman et al. 1998). So treatments that lower DHT, block the androgen receptor or restart growth rank above ones that act on circulation, nutrition or the hair shaft. On evidence, large, long, placebo-controlled, independent trials count most. Our treatment science library grades many of these treatments one at a time.

Anagen sells products that contain many of the treatments on this list and lists a hair supplement on a waitlist. We say so at each one. Anagen and HairDAO also fund research on TWIST1 inhibition and topical R-spondins, both on Anagen's research map. Compounded drugs are not FDA approved or tested in their own efficacy trials. Numbers from our own measurements are labelled as ours.

What is the best hair loss treatment in 2026?

If you want the best-proven option, it is still finasteride, dutasteride or minoxidil, all in A tier. S tier ranks higher on mechanism alone.

S tier

TWIST1 inhibitor. It sits in S because its target comes from a genetic risk locus. That is a different starting point from lowering DHT or opening potassium channels. TWIST1 is a transcription factor in the dermal papilla, the cells that set how a follicle grows. Comparing one balding and one non-balding papilla cell line, researchers named TWIST1 the relevant gene at a pattern hair loss risk locus (Chew et al. 2016). Switching Twist1 off in young mice kept follicles growing (Xu et al. 2013).

But its effect in the papilla is contested, and no inhibitor has reached a person. Deleting Twist1 in mouse bulge cells cost them stem cell markers (Eguiarte-Solomon et al. 2021). The program Anagen and HairDAO fund is at the cell-culture stage.

R-spondin. It sits in S because it acts on the growth signal itself, while every A tier drug lowers DHT or opens potassium channels. R-spondins are proteins that amplify Wnt, the signal that starts a follicle's growth phase. Injecting RSPO1 into resting mouse skin pushed follicles into growth early (Li et al. 2016). There are no human data, though, and R-spondin only amplifies Wnt that is already present. Lifelong overexpression of a relative, RSPO3, gave mice sparse hair (Olczak et al. 2024).

MINX is Anagen's smooth-release oral minoxidil with an active dose of vitamin D (500 IU). Anagen sells this compounded capsule. MINX aims to release minoxidil more smoothly than an immediate release tablet, and it sits in S on mechanism and that design rationale. It has not been measured for hair or tolerability outcomes. Oral minoxidil itself is off-label for hair loss in the US. In a double-blind trial of 90 men, 5 mg a day did not prove superior to topical 5% over 24 weeks (Penha et al. 2024).

Precision Dutasteride 1% (sold as Precision Dutasteride Max) aims to keep dutasteride's action in the scalp. Anagen sells this compounded topical dutasteride. It has not been tested for hair, and the hair evidence for dutasteride comes from oral capsules (Gubelin Harcha et al. 2014). In our two-person blood check of the 1% strength, serum dutasteride was below 0.1 ng/mL at day 4, and 0.157 and 0.282 ng/mL at day 30. After a year of oral 0.5 mg it is 40 ng/mL (GlaxoSmithKline 2020), though the two sets of figures are not directly comparable.

A tier

Dutasteride, finasteride and minoxidil earn A on human evidence. Diazoxide and 17β-estradiol are here on mechanism, ahead of their human data.

  • Dutasteride blocks both type 1 and type 2 5-alpha-reductase, the enzymes that make DHT. In 917 men, 0.5 mg a day raised hair count at 24 weeks more than finasteride 1 mg (P = .003) and placebo (Gubelin Harcha et al. 2014). It is off-label for hair loss in the US. Anagen sells oral dutasteride capsules. Our finasteride vs dutasteride post compares the two.
  • Finasteride blocks type 2 5-alpha-reductase and is FDA approved at 1 mg. In two 1-year trials of 1,553 men, it beat placebo by 107 hairs at one year and 138 at two, in a 5.1 cm² crown patch (Kaufman et al. 1998). Men on placebo kept losing hair. Anagen sells finasteride 1 mg tablets and topical finasteride.
  • Minoxidil opens potassium channels in the follicle once scalp enzymes convert it to minoxidil sulfate. Topical 5% is FDA approved. Over 48 weeks in 393 men, it added 18.6 non-vellus hairs per cm², against 12.7 on 2% and 3.9 on placebo (Olsen et al. 2002). Anagen sells oral minoxidil tablets and topical minoxidil 5%.
  • Diazoxide opens the same potassium channel family as minoxidil's active form, without needing the scalp enzyme SULT1A1. Topical diazoxide maintained or thickened frontal hair in all five treated balding macaques over 16 months, and three showed progressive regrowth (Uno et al. 1990). The oral drug's label lists excess hair growth as a frequent side effect. But no controlled human trial has tested topical diazoxide for hair loss. Anagen sells a compounded 3% Topical Diazoxide.
  • 17β-estradiol is the body's main estrogen. In isolated human dermal papillae it cut DHT formation by 60% at 100 nM (Niiyama et al. 2001), and this placement rests mostly on that mechanism. We found no topical 17β-estradiol trial whose results we could verify. Ethinylestradiol added to 2% minoxidil gave no significant advantage in 43 women (Bedair et al. 2025). In mice, topical 17β-estradiol held follicles at rest (Oh and Smart 1996). Anagen sells an estradiol patch for menopause.

Which hair loss treatments are promising but unproven?

Look in B and C tier. Each has a mechanism that fits pattern hair loss, but its human hair data are small, mixed, company-reported or missing. Any of them could move as trials report.

B tier

  • Microneedling rolls fine needles over the scalp. In a 100-man pilot with no sham control, adding weekly microneedling to 5% minoxidil raised the 12-week hair count gain from 22.2 to 91.4 per cm² (Dhurat et al. 2013). A later open-label trial in 245 women found no added benefit over 2% minoxidil alone at 24 weeks (Liu et al. 2026).
  • RU58841 is a topical androgen receptor blocker sold online as an unapproved research chemical. No efficacy trial has been published. The only human study of RU58841 gave six men a single scalp dose. Blood levels peaked within 12 hours and fell to near baseline by 36 hours, which the authors called considerable systemic exposure (Okutan et al. 2026).
  • Bicalutamide is an oral androgen receptor blocker used off-label in women. In the only randomized trial we found, 74 women took 1 mg oral minoxidil with or without 25 mg bicalutamide. Adding it gave no extra density gain (18.1 against 21.5 hairs per cm², P = .86). Fewer women on the combination had facial hypertrichosis at 24 weeks (49% against 73%, P = .03) (Libório et al. 2025).
  • Darolutamide is an androgen receptor blocker approved for prostate cancer. We found no hair data, so it ranks on mechanism alone.
  • Dimethylcurcumin (ASC-J9) increased breakdown of a mutant androgen receptor in cells, while treated mice kept serum testosterone nearly unchanged (Yang et al. 2007). It has no hair data. As an acne cream in 181 people, it missed its primary endpoint against vehicle (NCT01289574).

C tier

  • WAY-316606 blocks SFRP1, a protein that dampens Wnt signalling. In organ-cultured human scalp follicles, it increased hair shaft growth within two days (Hawkshaw et al. 2018). It has not been tested on a person.
  • ABS-201 is Absci's antibody against the prolactin receptor. Absci has reported lab data on ABS-201 from cultured human scalp skin (Absci 2025) and a mouse study (Absci 2026), but no human hair counts. Its Phase 1/2 trial is recruiting.
  • KY19382 is a Wnt-activating small molecule. It regrew mouse hair more than minoxidil over 28 days (Ryu et al. 2021). There are no human data.
  • Fluridil is a topical androgen receptor blocker. In a double-blind trial in 43 men, the share of growing hairs on a trichogram rose from 76% to 85% at three months (Sovak et al. 2002). Placebo did not change.
  • T3 (liothyronine) is thyroid hormone. On cultured human scalp skin, topical T3 showed pilot signs of stimulating growth, in a study HairDAO co-authored and patented (Gherardini et al. 2025). In a 10-person alopecia areata trial, it did no better than placebo (Nasiri et al. 2012). Anagen sells a compounded topical T3.
  • Ketoconazole is an antifungal shampoo. In a non-randomized 21-month study of 39 men, ketoconazole shampoo improved a growth and shaft-thickness index over plain shampoo. In an 8-man comparison, density rose 18% on it and 11% on 2% minoxidil (Piérard-Franchimont et al. 1998). Two of the authors came from its maker. Anagen sells a prescription 2% ketoconazole shampoo.
  • Latanoprost is a prostaglandin glaucoma drug. Sixteen men each treated one scalp patch with 0.1% latanoprost and another with placebo. At 24 weeks, density reached 122% of baseline on latanoprost against 110% on placebo (Blume-Peytavi et al. 2012). Anagen sells a compounded 0.1% topical latanoprost.
  • Bimatoprost is the related eyelash drug. In Allergan's unpublished Phase 2 trial in 307 men, its best formula added 13.1 hairs per cm² at six months, against 4.1 on vehicle and 21.9 on 5% minoxidil (NCT01325337). Our bimatoprost vs latanoprost post compares the two.
  • Clascoterone is a topical androgen receptor blocker, FDA approved for acne as Winlevi. Cosmo Pharmaceuticals reported that clascoterone beat vehicle on target-area hair count in two Phase 3 trials with 1,465 patients. The release gave relative improvements of 539% and 168% over the vehicle result, and no absolute counts (Cosmo 2025).
  • ET-02 is an unnamed topical small molecule. In a 24-person, four-week Phase 1, Eirion Therapeutics reported a 6-fold increase in non-vellus hair count at the 5% dose, against a pooled vehicle and 1.25% dose group. Eirion gave no absolute counts or p-values (Eirion 2025), and expects Phase 2 to begin in 2027 (Eirion 2026).

Why do PRP, laser helmets and Nutrafol rank so low?

They do have human trials, and so do saw palmetto, pumpkin seed oil and caffeine. But in our read the gains were modest, or the trials were small, short, unblinded, placebo-free or paid for by the maker.

D tier

D holds plausible mechanisms with very little human hair data, or company results we cannot yet read in full.

  • GHK-Cu is a copper-binding peptide common in hair serums. We found no placebo-controlled trial of it alone for pattern hair loss. The only controlled trial of a GHK compound we found used a copper-free conjugate (Lee et al. 2016).
  • Levocetirizine is an antihistamine. In a dish, it lowered prostaglandin D2 and raised human papilla cell growth (Wen et al. 2020). We found no hair study of it in people. Its parent drug, cetirizine, added no density benefit to 5% minoxidil in a double-blind trial of 66 women (Bassiouny et al. 2023). Several of Anagen's topical combinations contain cetirizine 1%.
  • Melatonin was tested at 0.1% in a 40-woman placebo-controlled pilot. In the 12 women with pattern hair loss, the share of growing hairs at the back of the scalp rose from 76.3% to 85% (P = .012 against placebo). There was no significant change at the front (Fischer et al. 2004). Anagen's Au Naturale topical contains melatonin.
  • Progesterone at 1 nM cut DHT formation by 75% in isolated human papillae (Niiyama et al. 2001). But we found no controlled hair trial, and a 2021 review found no study of it on menopausal scalp hair (Gasser et al. 2021). Anagen sells a MINX + Progesterone Capsule.
  • Pyrilutamide (KX-826) is a topical androgen receptor blocker. Its maker reported that pyrilutamide beat placebo by 10.65 hairs per cm² at 24 weeks in 666 Chinese men (Kintor 2026). An earlier Chinese Phase 3 missed significance (Kintor 2023). Neither result has a paper yet.
  • Adenosine lotion raised the proportion of thick hairs against placebo in 38 men, in a trial by Shiseido researchers (Iwabuchi et al. 2016). But a 2025 meta-analysis found no significant pooled effect on density (Szendzielorz and Spiewak 2025). Anagen's Au Naturale topical contains adenosine.
  • NAC ethyl ester is a cell-permeable form of the antioxidant N-acetylcysteine. We found no hair or follicle data for it.
  • PP405 is Pelage Pharmaceuticals' investigational topical gel. Pelage ran a four-week Phase 2a of PP405 in 78 people. It reported that 31% of men with more advanced loss had a more than 20% density gain at week 8, against 0% on placebo (Pelage 2025). Pelage did not give the size of that subgroup.
  • HMI-115 is Hope Medicine's injected antibody against the prolactin receptor. The company reported a gain of 14 hairs per cm² in 12 men in an open-label Phase 1b (Hope Medicine 2024). Its 192-man placebo-controlled Phase 2 (NCT06118866) finished in November 2024 without posting results.
  • Hyaluronic acid is the active in Amplifica's AMP-303. Its patent application describes 0.3% non-crosslinked hyaluronic acid injected into the scalp (Fazio et al. 2024). Amplifica reported that a "statistically significant percentage" of men had a more than 15% hair count rise at day 60 against the placebo side. The company gave no numbers (Amplifica 2024).

F tier

F means little or no good evidence of benefit for pattern hair loss, in our read. Besides the weak trials above, some entries were never tested, have a mechanism that does not fit, or look unstable in lab data.

  • Pumpkin seed oil capsules, 400 mg a day, raised hair count 40% over 24 weeks in 76 men, against 10% on placebo (Cho et al. 2014). That is one trial, funded by the capsule's supplier, and the paper does not give the capsule's full composition. Anagen lists a hair supplement containing pumpkin seed oil, currently on a waitlist.
  • Rosemary oil: in a six-month trial of rosemary oil vs minoxidil in 100 men, hair counts did not differ significantly (Panahi et al. 2015). The trial had no placebo arm and used the weaker 2% minoxidil.
  • Vitamins help hair when you are deficient. A review of biotin found that all 18 reported cases of benefit had an underlying cause (Patel et al. 2017).
  • Mineral oils did not reduce protein loss from hair fibres in lab tests (Rele and Mohile 2003). We found no study that tested them for growth.
  • Alfatradiol (17α-estradiol) left density and thickness nearly unchanged over six months in 103 women, while 2% minoxidil raised both (Blume-Peytavi et al. 2007).
  • BPC-157: we found no hair study of it. The FDA's 2026 briefing document found no studies giving it to humans by the oral, subcutaneous, nasal or transdermal routes nominated for compounding.
  • Methyl vanillate, a Wnt activator, raised hair count 6% over six months in an uncontrolled study of 20 women (Tosti et al. 2016).
  • Caffeine 0.2% liquid was non-inferior to 5% minoxidil on the share of growing hairs in 210 men (Dhurat et al. 2017). The trial was open-label, had no placebo and was funded by the caffeine product's maker. Anagen's Au Naturale topical contains caffeine.
  • Methyl nicotinate, a niacin derivative, and arginine have no hair trial of their own that we could find.
  • Pentoxifylline: we found no trial in pattern hair loss. Its human hair data are injections into alopecia areata patches (El-Taweel and Akl 2019).
  • CosmeRNA is Bioneer's RNA-based scalp product aimed at the androgen receptor. On 15 November 2026, its site classed it as "a cosmetic and not a medicine". In two 24-week trials by Bioneer staff, total hair counts rose against each person's baseline. The rise was about 2.3 hairs per cm² over 24 weeks at the low dose, and about 1.3 to 1.9 hairs per cm² a month at the high dose. The authors described that as comparable to finasteride (Yun et al. 2022).
  • Stemoxydine is a L'Oréal ingredient. L'Oréal researchers reported three-month density gains a few percentage points above vehicle in three studies in men, published as a conference abstract (Loussouarn et al. 2012).
  • Minoxidil sulfate is minoxidil's active form, but lab data suggest it is unstable. Held for 22 hours in a pH 2 lab solution with methanol, more than 60% degraded at 25 °C and more than 85% at 37 °C (Ichida et al. 2020). At 4 °C, under 15% did. No finished minoxidil sulfate product has been tested.
  • Saw palmetto improved hair in 38% of men, against 68% on finasteride, in an open two-year trial of 100 men (Rossi et al. 2012). Its placebo-controlled trials are small or run by an extract's maker. In 80 people on a branded oil for 16 weeks, density rose about 5% with the oral form (Sudeep et al. 2023). Another gave 19 men a multi-ingredient softgel (Prager et al. 2002). In 60 adults on a proprietary extract, terminal hair count changed +18.6 against −10.1 on placebo at day 180 (Ablon 2026). Anagen's waitlisted supplement contains saw palmetto.
  • Carpronium chloride is a Japanese topical. Japan's national guideline rates it only "permissible", saying its efficacy "has not been sufficiently verified" (Manabe et al. 2018).
  • Scalp massage was tested in nine healthy men. Hair thickened from 0.085 to 0.092 mm over 24 weeks, with no significant difference from an unmassaged side, and hair density fell at 12 weeks (Koyama et al. 2016).
  • Laser helmets beat sham devices in short trials. In 41 men over 16 weeks, a 655 nm helmet added 67.2 hairs in a 2.85 cm² area, against 28.4 on sham (Lanzafame et al. 2013). A laser comb maker part-funded four sham-controlled trials of its device (Jimenez et al. 2014). Modest gains, short trials and maker funding keep them low.
  • PRP (platelet-rich plasma) added 27.55 hairs per cm² against placebo across 13 randomized trials (Kieling et al. 2024). The reviewers concluded that the studies suggest PRP increases hair density. They also rated the evidence low quality, for heterogeneity and publication bias.
  • Nutrafol, a supplement from Nutraceutical Wellness, raised terminal and vellus hair counts against placebo at 90 and 180 days in 40 women (Ablon and Kogan 2018). That trial had a company co-author. In a company-funded trial in men, imaging protocol deviations at one site meant the original hair-count primary endpoint could not be analysed. Blinded investigators did rate more men improved on the supplement than on placebo (Bhatia et al. 2025).
  • Deoxyribose gel (2-deoxy-D-ribose) regrew hair in testosterone-treated mice about as well as 2% minoxidil, in groups of four mice (Anjum et al. 2024).
  • SCUBE3 is a dermal papilla signalling protein. Injected into mice, it started new growth, including in human follicles grafted onto them (Liu et al. 2022). It has not been given to a person.

What are the side effects of the top-ranked hair loss treatments?

Side effects decided close placements between otherwise similar treatments.

The Propecia label reports three 12-month trials. In them, 3.8% of men on finasteride reported a sexual side effect against 2.1% on placebo, and 1.2% stopped because of one against 0.9% (Organon 2024). In the dutasteride trial, drug-related side effects ran at 16% on dutasteride 0.5 mg, 20% on finasteride 1 mg and 15% on placebo (Gubelin Harcha et al. 2014). Both labels tell women who are or may become pregnant not to handle crushed or broken finasteride tablets or dutasteride capsules (Organon 2024; GlaxoSmithKline 2020). The concern is a potential risk to a male fetus.

Oral minoxidil's most common effect is unwanted body or facial hair. It showed up in 22 of 45 men (49%) in one trial (Penha et al. 2024). In an open-label 5 mg study, it showed up in 93% of 30 men (Panchaprateep and Lueangarun 2020). Minoxidil tablets carry a boxed warning in their blood pressure labeling that they can cause pericardial effusion and worsen angina (AvKARE 2026).

Oral diazoxide treats low blood sugar from excess insulin (Chen et al. 2021), so we tracked glucose in three people using our topical diazoxide. Average glucose changed by +3.9 mg/dL (95% CI −1.4 to +9.1), which was not statistically significant (diazoxide science page). Three people without controls cannot exclude a rise of about 9 mg/dL.

What we do not know about these rankings

Few of these treatments have been tested against each other, and the trials enrolled different people for different lengths of time. Several newer numbers, for pyrilutamide, clascoterone, PP405, ET-02 and HMI-115, come from company announcements without a peer-reviewed paper. S tier is the least certain part by design, since none of its four has human outcome data. Placements will move as trials report, in either direction.

Frequently asked questions

What is the most effective hair loss treatment?

Finasteride, dutasteride and minoxidil have the most placebo-controlled evidence. Finasteride 1 mg added 138 hairs in a 5.1 cm² crown patch against placebo over two years. Dutasteride 0.5 mg beat finasteride 1 mg on hair count at 24 weeks in 917 men. Topical 5% minoxidil beat both 2% and placebo over 48 weeks.

Is oral minoxidil better than topical minoxidil?

Not clearly. In a double-blind trial of 90 men, oral minoxidil 5 mg a day did not prove superior to topical 5% over 24 weeks, although photographic assessment favoured oral at the crown. Nearly half the men on oral minoxidil grew unwanted body or facial hair. Oral minoxidil is off-label for hair loss in the US.

Does PRP work for hair loss?

A 2024 meta-analysis of 13 randomized trials found platelet-rich plasma added 27.55 hairs per cm² over placebo on average. The reviewers concluded the studies suggest PRP increases hair density. But they rated the evidence low quality, because the studies were highly heterogeneous and showed publication bias. That is why PRP ranks in F here.

Does Nutrafol work for hair loss?

In a 40-woman placebo-controlled trial with a company co-author, Nutrafol raised terminal and vellus hair counts at 90 and 180 days. In a company-funded trial in men, the hair-count endpoint could not be analysed, though blinded investigators rated more men improved on Nutrafol than on placebo. Our Nutrafol review has more.

Why does Anagen rank its own MINX and Precision Dutasteride in S tier?

MINX is Anagen's smooth-release oral minoxidil with 500 IU of vitamin D. Precision Dutasteride is Anagen's compounded topical dutasteride. Both contain drugs whose hair trials used other formulations, and both sit in S on mechanism and Anagen's design rationale. Neither has been measured for hair outcomes, and compounded drugs are not FDA approved.

References

  1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. DOI: 10.1016/s0190-9622(98)70007-6Cited in How did we rank hair loss treatments? · What is the best hair loss treatment in 2026?
  2. Chew EGY, Tan JHJ, Bahta AW, et al. Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. J Invest Dermatol. 2016;136(8):1559-1567. DOI: 10.1016/j.jid.2016.03.032Cited in What is the best hair loss treatment in 2026?
  3. Xu Y, Xu Y, Liao L, et al. Inducible knockout of Twist1 in young and adult mice prolongs hair growth cycle and has mild effects on general health, supporting Twist1 as a preferential cancer target. Am J Pathol. 2013;183(4):1281-1292. DOI: 10.1016/j.ajpath.2013.06.021Cited in What is the best hair loss treatment in 2026?
  4. Eguiarte-Solomon F, Blazanin N, Rho O, et al. Twist1 is required for the development of UVB-induced squamous cell carcinoma. Mol Carcinog. 2021;60(5):342-353. DOI: 10.1002/mc.23296Cited in What is the best hair loss treatment in 2026?
  5. Li N, Liu S, Zhang HS, et al. Exogenous R-Spondin1 induces precocious telogen-to-anagen transition in mouse hair follicles. Int J Mol Sci. 2016;17(4):582. DOI: 10.3390/ijms17040582Cited in What is the best hair loss treatment in 2026?
  6. Olczak A, Pieczonka TD, Ławicki S, et al. The overexpression of R-spondin 3 affects hair morphogenesis and hair development along with the formation and maturation of the hair follicle stem cells. Front Physiol. 2024;15:1424077. DOI: 10.3389/fphys.2024.1424077Cited in What is the best hair loss treatment in 2026?
  7. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600-605. DOI: 10.1001/jamadermatol.2024.0284Cited in What is the best hair loss treatment in 2026? · What are the side effects of the top-ranked hair loss treatments?
  8. Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3. DOI: 10.1016/j.jaad.2013.10.049Cited in What is the best hair loss treatment in 2026? (2) · What are the side effects of the top-ranked hair loss treatments?
  9. GlaxoSmithKline, AVODART (dutasteride) soft gelatin capsules: prescribing information. Revised January 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdfCited in What is the best hair loss treatment in 2026? · What are the side effects of the top-ranked hair loss treatments?
  10. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. DOI: 10.1067/mjd.2002.124088Cited in What is the best hair loss treatment in 2026?
  11. Uno H, Kemnitz JW, Cappas A, et al. The effects of topical diazoxide on hair follicular growth and physiology of the stumptailed macaque. J Dermatol Sci. 1990;1(3):183-194. DOI: 10.1016/0923-1811(90)90130-6Cited in What is the best hair loss treatment in 2026?
  12. Niiyama S, Happle R, Hoffmann R. Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol. 2001;11(3):195-198. PMID: 11358723Cited in What is the best hair loss treatment in 2026? · Why do PRP, laser helmets and Nutrafol rank so low?
  13. Bedair NI, El-Komy MHM, Mohamed RE, et al. Efficacy and safety of combined topical estradiol with minoxidil vs. topical minoxidil in female pattern hair loss: a trichoscopic randomized controlled trial. Clin Exp Dermatol. 2025;50(3):611-619. DOI: 10.1093/ced/llae436Cited in What is the best hair loss treatment in 2026?
  14. Oh HS, Smart RC. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci U S A. 1996;93(22):12525-12530. DOI: 10.1073/pnas.93.22.12525Cited in What is the best hair loss treatment in 2026?
  15. Dhurat R, Sukesh M, Avhad G, et al. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6-11. DOI: 10.4103/0974-7753.114700Cited in Which hair loss treatments are promising but unproven?
  16. Liu Y, Luo H, Yang S, et al. Microneedle frequency adjunct to 2% minoxidil in female androgenetic alopecia: a randomized controlled trial. J Am Acad Dermatol. 2026. Online ahead of print. DOI: 10.1016/j.jaad.2026.03.123Cited in Which hair loss treatments are promising but unproven?
  17. Okutan A, Krug O, Fußhöller G, et al. Investigation into the metabolism and elimination behavior of RU 58841, and its influence on the steroid profile in humans. Biomed Chromatogr. 2026;40(10):e70602. DOI: 10.1002/bmc.70602Cited in Which hair loss treatments are promising but unproven?
  18. Libório RDS, Motta AVD, Miot HA, et al. Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern hair loss: a randomized double-blind clinical trial. JAAD Int. 2025;19:48-55. DOI: 10.1016/j.jdin.2024.12.002Cited in Which hair loss treatments are promising but unproven?
  19. Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13(3):348-353. DOI: 10.1038/nm1547Cited in Which hair loss treatments are promising but unproven?
  20. Hawkshaw NJ, Hardman JA, Haslam IS, et al. Identifying novel strategies for treating human hair loss disorders: cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles. PLoS Biol. 2018;16(5):e2003705. DOI: 10.1371/journal.pbio.2003705Cited in Which hair loss treatments are promising but unproven?
  21. Absci Corporation. Absci reports new human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates stem cell niche to potentially reverse follicle miniaturization. Press release. 11 December 2025. https://www.globenewswire.com/news-release/2025/12/11/3203834/0/en/Cited in Which hair loss treatments are promising but unproven?
  22. Absci Corporation. Annual report on Form 10-K, filed 24 March 2026, for the fiscal year ended 31 December 2025. https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htmCited in Which hair loss treatments are promising but unproven?
  23. Ryu YC, Lee DH, Shim J, et al. KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br J Pharmacol. 2021;178(12):2533-2546. DOI: 10.1111/bph.15438Cited in Which hair loss treatments are promising but unproven?
  24. Sovak M, Seligson AL, Kucerova R, et al. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surg. 2002;28(8):678-685. DOI: 10.1046/j.1524-4725.2002.02017.xCited in Which hair loss treatments are promising but unproven?
  25. Gherardini J, Akhundlu A, Gompels M, et al. Pilot evidence that topically applied triiodothyronine can stimulate hair growth in human scalp skin. Clin Exp Dermatol. 2025;50(9):1862-1864. DOI: 10.1093/ced/llaf190Cited in Which hair loss treatments are promising but unproven?
  26. Nasiri S, Haghpanah V, Taheri E, et al. Hair regrowth with topical triiodothyronine ointment in patients with alopecia areata: a double-blind, randomized pilot clinical trial of efficacy. J Eur Acad Dermatol Venereol. 2012;26(5):654-656. DOI: 10.1111/j.1468-3083.2011.04088.xCited in Which hair loss treatments are promising but unproven?
  27. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. DOI: 10.1159/000017954Cited in Which hair loss treatments are promising but unproven?
  28. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794-800. DOI: 10.1016/j.jaad.2011.05.026Cited in Which hair loss treatments are promising but unproven?
  29. Cosmo Pharmaceuticals. Cosmo announces breakthrough Phase III topline results from Scalp 1 and Scalp 2 for clascoterone 5% solution in male hair loss. Press release. 3 December 2025. https://www.cosmohealthconfidence.com/news/11029858-breezula-phase-iii-resultsCited in Which hair loss treatments are promising but unproven?
  30. Eirion Therapeutics. Eirion Therapeutics announces potential breakthrough treatment for hair loss based on first-in-man clinical trial results. Press release. 8 January 2025. https://www.prnewswire.com/news-releases/eirion-therapeutics-announces-potential-breakthrough-treatment-for-hair-loss-based-on-first-in-man-clinical-trial-results-302344730.htmlCited in Which hair loss treatments are promising but unproven?
  31. Eirion Therapeutics. Eirion Therapeutics to present promising first-in-human ET-02 data at the Third BCN Hair Meeting. Press release. 16 September 2026. https://www.prnewswire.com/news-releases/eirion-therapeutics-to-present-promising-first-in-human-et-02-data-at-the-third-bcn-hair-meeting-302879501.htmlCited in Which hair loss treatments are promising but unproven?
  32. Lee WJ, Sim HB, Jang YH, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016;28(4):438-443. DOI: 10.5021/ad.2016.28.4.438Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  33. Wen S, Wei J, Bao J, et al. Effect of levocetirizine hydrochloride on the growth of human dermal papilla cells: a preliminary study. Ann Palliat Med. 2020;9(2):308-317. DOI: 10.21037/apm.2020.01.15Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  34. Bassiouny EA, El-Samanoudy SI, Abbassi MM, et al. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Arch Dermatol Res. 2023;315(5):1293-1304. DOI: 10.1007/s00403-022-02512-2Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  35. Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341-345. DOI: 10.1111/j.1365-2133.2004.05685.xCited in Why do PRP, laser helmets and Nutrafol rank so low?
  36. Gasser S, Heidemeyer K, von Wolff M, Stute P. Impact of progesterone on skin and hair in menopause: a comprehensive review. Climacteric. 2021;24(3):229-235. DOI: 10.1080/13697137.2020.1838476Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  37. Kintor Pharmaceutical. Phase III KX-826 tincture 1.0% for AGA reached primary endpoint. Press release. 18 March 2026. https://en.kintor.com.cn/news_details/22.htmlCited in Why do PRP, laser helmets and Nutrafol rank so low?
  38. Kintor Pharmaceutical. Results of KX-826 Phase III clinical trial for treatment of male AGA in China. HKEX announcement. 27 November 2023. https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1127/2023112700172.pdfCited in Why do PRP, laser helmets and Nutrafol rank so low?
  39. Iwabuchi T, Ideta R, Ehama R, et al. Topical adenosine increases the proportion of thick hair in Caucasian men with androgenetic alopecia. J Dermatol. 2016;43(5):567-570. DOI: 10.1111/1346-8138.13159Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  40. Szendzielorz E, Spiewak R. Adenosine as an active ingredient in topical preparations against hair loss: a systematic review and meta-analysis of published clinical trials. Biomolecules. 2025;15(8):1093. DOI: 10.3390/biom15081093Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  41. Pelage Pharmaceuticals. Pelage Pharmaceuticals announces positive Phase 2a clinical trial results for PP405 in regenerative hair loss therapy. Press release. 17 June 2025. https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  42. Hope Medicine, Positive outcome from a Phase Ib study in Australia treating patients with androgenic alopecia. Press release. 14 January 2024. https://www.biospace.com/positive-outcome-from-a-phase-ib-study-in-australia-treating-patients-with-androgenic-alopeciaCited in Why do PRP, laser helmets and Nutrafol rank so low?
  43. Fazio F, Wajdie A, Masi L. Compositions and methods for treatment of androgenetic alopecia. WO2024211282A1. Published 10 October 2024. https://patents.google.com/patent/WO2024211282A1/enCited in Why do PRP, laser helmets and Nutrafol rank so low?
  44. Amplifica, Amplifica's AMP-303 study unveils new hope for hair loss treatments. Press release. 30 September 2024. https://www.prnewswire.com/news-releases/amplificas-amp-303-study-unveils-new-hope-for-hair-loss-treatments-302261925.htmlCited in Why do PRP, laser helmets and Nutrafol rank so low?
  45. Cho YH, Lee SY, Jeong DW, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:549721. DOI: 10.1155/2014/549721Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  46. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15-21. PMID: 25842469Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  47. Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169. DOI: 10.1159/000462981Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  48. Rele AS, Mohile RB. Effect of mineral oil, sunflower oil, and coconut oil on prevention of hair damage. J Cosmet Sci. 2003;54(2):175-192. PMID: 12715094Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  49. Blume-Peytavi U, Kunte C, Krisp A, et al. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007;5(5):391-395. DOI: 10.1111/j.1610-0387.2007.06295.xCited in Why do PRP, laser helmets and Nutrafol rank so low?
  50. Tosti A, Zaiac MN, Canazza A, et al. Topical application of the Wnt/β-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia. J Cosmet Dermatol. 2016;15(4):469-474. DOI: 10.1111/jocd.12225Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  51. Dhurat R, Chitallia J, May TW, et al. An open-label randomized multicenter study assessing the noninferiority of a caffeine-based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol. 2017;30(6):298-305. DOI: 10.1159/000481141Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  52. El-Taweel AI, Akl EM. Intralesional pentoxifylline injection in localized alopecia areata. J Cosmet Dermatol. 2019;18(2):602-607. DOI: 10.1111/jocd.12796Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  53. Yun SI, Lee SK, Goh EA, et al. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep. 2022;12(1):1607. DOI: 10.1038/s41598-022-05544-wCited in Why do PRP, laser helmets and Nutrafol rank so low?
  54. Loussouarn G, El Rawadi C, Pineau I, et al. P040: Stemoxydine and hair kenogen phase in androgenetic alopecia (AGA). Int J Trichology. 2012;4(2):131. Conference abstract. https://pmc.ncbi.nlm.nih.gov/articles/PMC3500072/Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  55. Ichida M, Fujita C, Sumie R, Miyano R, Inoue H. Simultaneous determination of minoxidil and minoxidil sulfate by high-performance liquid chromatography with UV-detection and its applications. Med Drug Discov. 2020;7:100050. DOI: 10.1016/j.medidd.2020.100050Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  56. Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173. DOI: 10.1177/039463201202500435Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  57. Sudeep HV, Rashmi S, Jestin TV, et al. Oral and topical administration of a standardized saw palmetto oil reduces hair fall and improves the hair growth in androgenetic alopecia subjects: a 16-week randomized, placebo-controlled study. Clin Cosmet Investig Dermatol. 2023;16:3251-3266. DOI: 10.2147/CCID.S435795Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  58. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002;8(2):143-152. DOI: 10.1089/acm.2002.8.143Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  59. Ablon G. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. J Cosmet Dermatol. 2026;25(2):e70717. DOI: 10.1111/jocd.70717Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  60. Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031-1043. DOI: 10.1111/1346-8138.14470Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  61. Koyama T, Kobayashi K, Hama T, Murakami K, Ogawa R. Standardized scalp massage results in increased hair thickness by inducing stretching forces to dermal papilla cells in the subcutaneous tissue. Eplasty. 2016;16:e8. PMID: 26904154Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  62. Lanzafame RJ, Blanche RR, Bodian AB, et al. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013;45(8):487-495. DOI: 10.1002/lsm.22173Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  63. Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014;15(2):115-127. DOI: 10.1007/s40257-013-0060-6Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  64. Kieling L, Konzen AT, Zanella RK, Valente DS. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials. An Bras Dermatol. 2024;99(6):847-862. DOI: 10.1016/j.abd.2024.01.002Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  65. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565. PMID: 29742189Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  66. Bhatia N, Ablon G, Farris PK, Hazan A, Raymond I. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a nutraceutical supplement with standardized botanicals in males with thinning hair. J Cosmet Dermatol. 2025;24(1):e16778. DOI: 10.1111/jocd.16778Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  67. Anjum MA, Zulfiqar S, Chaudhary AA, et al. Stimulation of hair regrowth in an animal model of androgenic alopecia using 2-deoxy-D-ribose. Front Pharmacol. 2024;15:1370833. DOI: 10.3389/fphar.2024.1370833Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  68. Liu Y, Guerrero-Juarez CF, Xiao F, et al. Hedgehog signaling reprograms hair follicle niche fibroblasts to a hyper-activated state. Dev Cell. 2022;57(14):1758-1775.e7. DOI: 10.1016/j.devcel.2022.06.005Cited in Why do PRP, laser helmets and Nutrafol rank so low?
  69. Organon LLC. PROPECIA (finasteride) tablets: prescribing information. Label effective 14 October 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36Cited in What are the side effects of the top-ranked hair loss treatments? (2)
  70. Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345-1357. DOI: 10.1007/s13555-020-00448-xCited in What are the side effects of the top-ranked hair loss treatments?
  71. AvKARE, Minoxidil tablets USP: prescribing information, boxed warning. Label effective 21 January 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02d7399f-94cc-f718-f214-587301edd138Cited in What are the side effects of the top-ranked hair loss treatments?
  72. Chen X, Feng L, Yao H, Yang L, Qin Y. Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis. PLoS One. 2021;16(2):e0246463. DOI: 10.1371/journal.pone.0246463Cited in What are the side effects of the top-ranked hair loss treatments?
  73. Anagen. MINX: smooth-release oral minoxidil. Treatment science page. https://anagen.xyz/treatment-science/minx
  74. Anagen. Precision Dutasteride: follicular delivery monograph. Treatment science page. https://anagen.xyz/treatment-science/precision-dutasteride
  75. Anagen. Topical diazoxide for hair loss: the science and our data. Treatment science page, last reviewed 12 November 2026. https://anagen.xyz/treatment-science/diazoxide
  76. Anagen. TWIST1: target rationale and ASO screen. Treatment science page. https://anagen.xyz/treatment-science/twist1
  77. Teva Pharmaceuticals USA. PROGLYCEM (diazoxide) oral suspension: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf
  78. Bayer HealthCare Pharmaceuticals. NUBEQA (darolutamide): prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e
  79. US Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document, 23 to 24 July 2026: BPC-157-related bulk drug substances. https://www.fda.gov/media/193343/download
  80. AndroScience. Topical ASC-J9 cream for acne. ClinicalTrials.gov NCT01289574. https://clinicaltrials.gov/study/NCT01289574
  81. Allergan. Bimatoprost in the treatment of men with androgenic alopecia, posted results. ClinicalTrials.gov NCT01325337. https://clinicaltrials.gov/study/NCT01325337
  82. Hope Medicine. HMI-115 Phase 2 in male androgenetic alopecia. ClinicalTrials.gov NCT06118866. https://clinicaltrials.gov/study/NCT06118866
  83. CosmeRNA. What is CosmeRNA. Company page, accessed 15 November 2026. https://www.cosmerna.com/pages/what-is-cosmerna

This article is for educational purposes only and is not medical advice. Prescription drugs, including finasteride, dutasteride, oral minoxidil, bicalutamide and diazoxide, are decisions for a licensed clinician who knows your history; topical minoxidil and oral finasteride 1 mg are FDA approved for pattern hair loss, while oral minoxidil, dutasteride in any form and bicalutamide are used off-label. MINX, Precision Dutasteride, Topical Diazoxide and topical T3 are compounded Anagen products, are not FDA approved and have not been tested in their own efficacy trials. Several treatments named here, including RU58841 and BPC-157, are not approved by the FDA for any use, and nothing here recommends them.

Who wrote and reviewed this

Written by

Andrew Bakst

Co-founder, HairDAO

39 articles on the Anagen blog

First published
Last updated
References
83 sources

Start your personalised plan

Answer a few questions. We'll take it from there.

Take the hair assessment

Keep reading